The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Revenue from operations rose to Rs. 23,637 million for the three months ended December 31, 2025
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The revenues this quarter are in line with the outlook we envisaged for the year
The company’s EBITDA margin remained resilient above 20%
Subscribe To Our Newsletter & Stay Updated